Skip to main content
SpringerLink
Log in

Neue FLT3 Inhibitoren bei der AML und andere Targets

  • onkologie aktuell
  • Published:
InFo Hämatologie + Onkologie Aims and scope

Was kommt nach Midostaurin? Derzeit werden bei der FLT3-mutierten akuten myeloischen Leukämie (FLT3-AML) Inhibitoren der nächsten TKI-Generationen entwickelt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Bericht vom International Symposium Acute Leukemias XVII vom 24. bis 27. Februar 2019 in Münchenn

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Carola Göring

Authors
  1. Carola Göring
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Göring, C. Neue FLT3 Inhibitoren bei der AML und andere Targets. Info Onkol. 22, 45–46 (2019). https://doi.org/10.1007/s15004-019-6438-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6438-8

Search

Navigation